Home
Virus
Gene
Disease
Dataset
Download
Help
 
Overview of HIV associated HIV infection/AIDS

Human immunodeficiency virus infection is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV). Following initial infection a person may not notice any symptoms, or may experience a brief period of influenza-like illness. Typically, this is followed by a prolonged period with no symptoms. Acquired immunodeficiency syndrome (AIDS) is defined as an HIV infection with either a CD4+ T cell count below 200 cells per µL or the occurrence of specific diseases associated with HIV infection.


ID Literature Title Group
1 30061964 Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis.
Mutation
2 30048246 Extensive host immune adaptation in a concentrated North American HIV epidemic.
Mutation
3 30046244 Higher Frequency of HIV-1 Drug Resistance and Increased Nucleoside Reverse Transcriptase Inhibitor Mutations among the HIV-1 Positive Antiretroviral Therapy-Naïve patients Coinfected With Mycobacterium tuberculosis Compared With Only HIV Infection in India.
Mutation
4 30040081 Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy.
Mutation
5 30016324 HIV-1 infection among crack cocaine users in a region far from the epicenter of the HIV epidemic in Brazil: Prevalence and molecular characteristics.
Mutation
6 29975689 HIV-1 diversity among young women in rural South Africa: HPTN 068.
Mutation
7 29953436 Genotyping performance evaluation of commercially available HIV-1 drug resistance test.
Mutation
8 29950423 HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Mutation
9 29892199 Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study.
Mutation
10 29884219 Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco.
Mutation
11 29870534 Epidemiological surveillance of HIV-1 transmitted drug resistance among newly diagnosed individuals in Shijiazhuang, northern China, 2014-2015.
Mutation
12 29861843 HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan.
Mutation
13 29856864 Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
Mutation
14 29846534 Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.
Mutation
15 29769530 Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.
Mutation
16 29732898 Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
Mutation
17 29698467 HIV-1 genetic transmission networks among men who have sex with men in Kunming, China.
Mutation
18 29684083 HIV-1 transmission networks across Cyprus (2010-2012).
Mutation
19 29683856 Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Mutation
20 29672607 Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma.
Mutation
21 28679441 HIV-1 genetic diversity and primary drug resistance mutations before large-scale access to antiretroviral therapy, Republic of Congo.
Mutation
22 28604824 Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial.
Mutation
23 28301548 HIV-1 genetic diversity and antiretroviral drug resistance among individuals from Roraima state, northern Brazil.
Mutation
24 28167814 Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland.
Mutation
25 28159573 Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller.
Mutation
26 28149058 Effect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data.
Mutation
27 28107423 Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.
Mutation
28 28099515 Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.
Mutation
29 27736898 HIV Drug Resistance in Antiretroviral Treatment-Naïve Individuals in the Largest Public Hospital in Nicaragua, 2011-2015.
Mutation
30 27367488 The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
Mutation
31 27353350 HIV Drug Resistance in Antiretroviral-Naive Patients in Mexico After 10 Years: Is There a Difference?
Mutation
32 27125365 Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
Mutation
33 25487529 HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.
Mutation
34 25397491 Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany.
Mutation
35 25397490 Viral escape in the CNS with multidrug-resistant HIV-1.
Mutation
36 25314293 Development and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptase.
Mutation
37 24616600 Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates.
Mutation
38 31574109 Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil.
Mutation
39 31443633 Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Mutation
40 31416460 Human immunodeficiency virus type 1 ((HIV-1) subtypes in the northwest region, Cameroon.
Mutation
41 31353798 Near full genome characterization of HIV-1 unique recombinant forms in Cameroon reveals dominant CRF02_AG and F2 recombination patterns.
Mutation
42 31266818 Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.
Mutation
43 31257432 Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
Mutation
44 31228958 Two-year cross-sectional studies reveal that single, young MSMs in Shenzhen, China are at high risk for HIV infection.
Mutation
45 31190911 Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam.
Mutation
46 31178836 Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity.
Mutation
47 31143232 HIV drug resistance among naïve HIV-infected patients in Iran.
Mutation
48 30379960 Prevalence of HIV-1 pretreatment drug resistance among treatment naïve pregnant women in Bissau, Guinea Bissau.
Mutation
49 30356083 Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence.
Mutation
50 30314470 Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.
Mutation
51 30309385 Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea.
Mutation
52 30305383 Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.
Mutation
53 30304061 HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013.
Mutation
54 30286160 HIV-1C proviral DNA for detection of drug resistance mutations.
Mutation
55 30249546 Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control.
Mutation
56 23144802 Screening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in China.
Mutation
57 21754996 Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.
Mutation
58 21655245 Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.
Mutation
59 20578491 Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).
Mutation
60 17194486 Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.
Mutation
61 32368103 HIV-1 Drug Resistance in ART-Naïve Individuals in Myanmar.
Mutation
62 32267869 Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria.
Mutation
63 32106437 Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
Mutation
64 32049783 High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Mutation
65 31037930 Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
Mutation
66 31024744 Consensus Integrase of a New HIV-1 Genetic Variant CRF63_02A1.
Mutation
67 31010245 Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort.
Mutation
68 30989237 Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
Mutation
69 30964884 Validation of publicly-available software used in analyzing NGS data for HIV-1 drug resistance mutations and transmission networks in a Washington, DC, Cohort.
Mutation
70 30961560 Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China.
Mutation
71 30937190 Primary HIV Drug Resistance among Recently Infected Cases of HIV in North-West India.
Mutation
72 30906285 A 28-Year History of HIV-1 Drug Resistance and Transmission in Washington, DC.
Mutation
73 30894467 Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
Mutation
74 30891603 High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
Mutation
75 30871487 HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Mutation
76 30798695 HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial.
Mutation
77 30759103 Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from rural coastal Kenya.
Mutation
78 30714528 Molecular Antiretroviral Resistance Markers of Human Immunodeficiency Virus-1 of CRF01_AE Subtype in Bali, Indonesia.
Mutation
79 30650082 Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.
Mutation
80 30640198 High Levels of HIV-1 Drug Resistance in Children Who Acquired HIV Infection Through Mother to Child Transmission in the Era of Option B+, Haiti, 2013 to 2014.
Mutation
81 30621727 Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.
Mutation
82 30577760 Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.
Mutation
83 30568984 Human Immunodeficiency Virus-1 Drug Resistance Patterns Among Adult Patients Failing Second-Line Protease Inhibitor-Containing Regimens in Namibia, 2010-2015.
Mutation
84 30562356 HIV-1 subtype diversity, transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya.
Mutation
85 30538823 Maintenance and reappearance of extremely divergent intra-host HIV-1 variants.
Mutation
86 30408827 Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
Mutation
87 30151407 Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort.
Mutation
88 30148406 Prevalence of Darunavir Resistance in the United States from 2010 to 2017.
Mutation
89 30134290 HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
Mutation
90 30122963 HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan.
Mutation
91 17697319 High genetic variability of HIV-1 in female sex workers from Argentina.
Mutation
92 17634131 Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source.
Mutation
93 17630831 HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.
Mutation
94 17620130 Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.
Mutation
95 30115986 Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China.
Mutation
96 30079168 Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso.
Mutation
97 18666824 Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
Mutation
98 18645523 In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression.
Mutation
99 18614915 Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants.
Mutation
100 18582198 Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
Mutation
101 18570675 Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania.
Mutation
102 18419497 Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Mutation
103 18369479 Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.
Mutation
104 18335052 Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients.
Mutation
105 32434561 Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi.
Mutation
106 32392227 Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.
Mutation
107 32371875 HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China.
Mutation
108 32280691 HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Mutation
109 32218587 Characterization of HIV-1 genetic diversity and antiretroviral resistance in the state of Maranhão, Northeast Brazil.
Mutation
110 32216752 The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.
Mutation
111 32214358 Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001-2016.
Mutation
112 32158555 Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy.
Mutation
113 32116431 Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya.
Mutation
114 32105319 High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
Mutation
115 32102660 Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Mutation
116 32046664 The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
Mutation
117 32045455 HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo.
Mutation
118 32041622 HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Mutation
119 32029767 A cross-sectional study to characterize local HIV-1 dynamics in Washington, DC using next-generation sequencing.
Mutation
120 32005262 Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Mutation
121 31956856 Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
Mutation
122 31929566 High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania - A prospective cohort study.
Mutation
123 31927793 Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Mutation
124 31889319 Analyses of HIV-1 integrase gene sequences among treatment-naive patients in the Eastern Cape, South Africa.
Mutation
125 31878069 Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis.
Mutation
126 31830799 HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.
Mutation
127 31819984 Pretreatment HIV drug resistance spread within transmission clusters in Mexico City.
Mutation
128 31773888 HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.
Mutation
129 31770425 Genetic diversity and drug resistance of HIV-1 among infected pregnant women newly diagnosed in Luanda, Angola.
Mutation
130 31754119 Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.
Mutation
131 31751428 Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Mutation
132 31745412 HIV Drug Resistance among Patients Failing Therapy at a Tertiary Center in Oman: A Case Record Review.
Mutation
133 31693887 Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity.
Mutation
134 31683782 HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses.
Mutation
135 31660328 Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.
Mutation
136 31651864 HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017.
Mutation
137 31330378 Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Mutation
138 31432614 Lack of effectiveness of adherence counselling in reversing virological failure among patients on long-term antiretroviral therapy in rural Uganda.
Mutation
139 31552748 Mexican HIV-1 Protease Sequence Diversity.
Mutation
140 31678241 Natural presence of V179E and rising prevalence of E138G in HIV-1 reverse transcriptase in CRF55_01B viruses.
Mutation
141 31741096 HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients.
Mutation
142 31764077 Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy.
Mutation
143 31776582 Erratum to: Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012.
Mutation
144 31818716 Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
Mutation
145 31833849 Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Mutation
146 31905383 Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Mutation
147 31915716 Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations.
Mutation
148 31922120 Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa.
Mutation
149 31926287 Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Mutation
150 31959116 Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study.
Mutation
151 31976534 Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Mutation
152 31982483 Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Mutation
153 32025714 Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda.
Mutation
154 32030406 The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.
Mutation
155 32081778 High rates of tenofovir failure in a CRF01_AE-predominant HIV epidemic in the Philippines.
Mutation
156 32094387 High HIV-1 diversity in immigrants resident in Italy (2008-2017).
Mutation
157 32096745 Analysis of Vpr Genetic Variations between Chinese Major Circulating Recombinants CRF01_AE and CRF07_BC.
Mutation
158 32102090 Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences.
Mutation
159 32119663 Zimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes.
Mutation
160 32125378 Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains.
Mutation
161 32126792 Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen.
Mutation
162 32154864 Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.
Mutation
163 32175088 Chorea associated with persistent low-level viremia in a patient living with HIV: a case report.
Mutation
164 32259255 Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
Mutation
165 32264923 Multidrug-resistant HIV viral rebound during early syphilis: a case report.
Mutation
166 32265875 Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Mutation
167 32267205 Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial.
Mutation
168 32279138 Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017-2019).
Mutation
169 32294040 Genetic Diversity and Drug Resistance of HIV-1 CRF55_01B in Guangdong, China.
Mutation
170 32295123 Molecular Epidemiology of the HIV-1 Subtype B Sub-Epidemic in Bulgaria.
Mutation
171 32300784 Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China.
Mutation
172 32345262 Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains.
Mutation
173 32360523 HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
Mutation
174 32370607 First Detection of a Circulating Recombinant Form of HIV-1 CRF01_AE/08_BC (CRF105_0108) with Drug-Resistant Mutations in Sichuan, China.
Mutation
175 32376625 Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
Mutation
176 32438914 Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
Mutation
177 32450199 Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Mutation
178 32464638 In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
Mutation
179 32475121 High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.
Mutation
180 32481261 Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study.
Mutation
181 32490370 Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women.
Mutation
182 32500372 Retrospective analysis of HIV-1 drug resistance mutations in Suzhou, China from 2009 to 2014.
Mutation
183 32510047 HIGH-FREQUENCY failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE.
Mutation
184 32522826 Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries.
Mutation
185 32539490 HIV-1 Genetic Diversity and High Prevalence of Pretreatment Drug Resistance in Tianjin, China.
Mutation
186 32541474 Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India.
Mutation
187 32556165 HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Mutation
188 32629687 Occurrence of the S230R integrase strand inhibitor mutation in a treatment-naïve individual case report.
Mutation
189 32642769 Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.
Mutation
190 32669335 A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mutation
191 32669382 A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings.
Mutation
192 32692778 Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.
Mutation
193 32694410 Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries.
Mutation
194 32709248 Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana.
Mutation
195 32711474 Immune escape mutations in HIV-1 controllers in the Brazilian Amazon region.
Mutation
196 32752001 Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
Mutation
197 32756581 Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
Mutation
198 32772079 Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals.
Mutation
199 32804970 Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Mutation
200 32858802 Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
Mutation
201 32873064 Genetic Characteristics of HIV-1 CRF12_BF First Identified in Guangdong Province, China.
Mutation
202 32877546 From Hospital to the Community: Redesigning the Human Immunodeficiency Virus (HIV) Clinical Service Model to Respond to an Outbreak of HIV Among People Who Inject Drugs.
Mutation
203 32878449 Genetic Diversity, Complicated Recombination, and Deteriorating Drug Resistance Among HIV-1-Infected Individuals in Wuhan, China.
Mutation
204 32879304 Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection.
Mutation
205 32925973 Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5.
Mutation
206 32936523 HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates.
Mutation
207 32946725 Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001-20181.
Mutation
208 32972239 Molecular Epidemiology of HIV-1 in Jiangsu Province, Southeast China: Genotypes and HIV-1 Transmission Networks Among Newly Diagnosed Men Having Sex with Men in 2017.
Mutation
209 33014372 Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.
Mutation
210 33031103 Critical effect of Pol escape mutations associated with detrimental allele HLA-C*15: 05 on clinical outcome in HIV-1 subtype A/E infection.
Mutation
211 33031315 Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana.
Mutation
212 33037235 Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017).
Mutation
213 33076683 Comparison of the Virological Response According to the Antiretroviral Regimens in Peruvian HIV Patients Who Presented the M184V Mutation in Two National Hospitals During the Years 2008 to 2019.
Mutation
214 33117613 Genetic and Functional Characterization of HIV-1 Vpu from HIV-1-Infected North Indian Population.
Mutation
215 33119663 Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic.
Mutation
216 33122923 Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study.
Mutation
217 33136738 High Prevalence of HIV-1 Drug Resistance and Dynamics of Transmission Among High-Risk Populations in Port-au-Prince, Haiti.
Mutation
218 33143301 Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations.
Mutation
219 33143751 Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
Mutation
220 33144375 In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.
Mutation
221 33170745 Determination of reverse transcriptase inhibitor resistance mutations in HIV-1 infected children in Côte d'Ivoire.
Mutation
222 33170863 Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Mutation
223 33173092 Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals.
Mutation
224 33184634 Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.
Mutation
225 33200210 Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
Mutation
226 33204746 Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data.
Mutation
227 33217873 Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV.
Mutation
228 33228206 Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Mutation
229 33246440 Identification and differential expression of serotransferrin and apolipoprotein A-I in the plasma of HIV-1 patients treated with first-line antiretroviral therapy.
Mutation
230 33247553 Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
Mutation
231 33252379 Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Mutation
232 33262331 Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase.
Mutation
233 33285702 Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia.
Mutation
234 33287631 Near Full-Length Genomic Characterization of a Novel HIV-1 B/C Recombinant Form Identified in Guangdong Province, China.
Mutation
235 33324078 Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018.
Mutation
236 33347449 The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.
Mutation
237 33364799 Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naïve Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan.
Mutation
238 33369017 Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Mutation
239 33390085 Detection of Drug Resistance Mutations in the Reverse Transcriptase Gene of HIV-1-Infected North Indian Population Failing First-Line Antiretroviral Therapy "A Follow-Up Cohort Study".
Mutation
240 33409332 A Low Level of Darunavir Resistance-Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort.
Mutation
241 33437166 The frequency of defective genes in vif and vpr genes in 20 hemophiliacs is associated with Korean Red Ginseng and highly active antiretroviral therapy: the impact of lethal mutations in vif and vpr genes on HIV-1 evolution.
Mutation
242 27181553 CD8 Encephalitis Caused by Persistently Detectable Drug-resistant HIV.
Mutation
243 25397436 Using dried blood spots collected under field condition to determine HIV-1 diversity and drug resistance mutations in resource limited Tanzania.
Mutation
244 25253273 HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.
Mutation
245 31591964 Epistasis and entrenchment of drug resistance in HIV-1 subtype B.
Mutation
246 31551948 Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.
Mutation
247 31535044 Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County.
Mutation
248 31143879 Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.
Mutation
249 30401010 Characterisation of HIV-1 transmission clusters and drug-resistant mutations in Denmark, 2004 to 2016.
Mutation
250 30352054 Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
Mutation
251 30277466 A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Mutation
252 16524459 DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.
Mutation
253 15839752 Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.
Mutation
254 15067030 Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection.
Mutation
255 11157057 Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.
Mutation
256 31117863 HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
Mutation
257 30863788 Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.
Mutation
258 30648124 Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.
Mutation
259 30596682 First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium.
Mutation
260 30568974 Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir.
Mutation
261 30544247 Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.
Mutation
262 30477526 Long-term virological outcome in children receiving first-line antiretroviral therapy.
Mutation
263 17958917 Functional relevance of nonsynonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort.
Mutation
264 17311088 Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape.
Mutation
265 17280617 Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).
Mutation
266 19918107 Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.
Mutation
267 31965175 Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.
Mutation
268 31832485 Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.
Mutation
269 31776278 Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
Mutation
270 31801029 A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis.
Mutation
271 32082657 Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era.
Mutation
272 32141388 Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study.
Mutation
273 32413134 Differential detection of M184V/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs.
Mutation
274 32675772 Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
Mutation
275 32715952 Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection.
Mutation
276 33290394 RV144 HIV-1 vaccination impacts post-infection antibody responses.
Mutation
277 33329900 Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting.
Mutation
278 11581417 Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences.
Mutation
279 11737863 Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients.
Mutation
280 12657161 Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002.
Mutation
281 17500586 HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
Mutation
282 17559687 Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.
Mutation
283 17710130 Differential drug resistance acquisition in HIV-1 of subtypes B and C.
Mutation
284 18052601 N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Mutation
285 18221530 Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.
Mutation
286 18271957 Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.
Mutation
287 18304321 Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.
Mutation
288 18645515 Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.
Mutation
289 18684096 Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
Mutation
290 18992847 Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
Mutation
291 19005273 Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.
Mutation
292 19005274 Transmission networks of drug resistance acquired in primary/early stage HIV infection.
Mutation
293 20030841 Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.
Mutation
294 20102271 Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Mutation
295 20102272 Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
Mutation
296 20158398 Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Mutation
297 20174661 HIV drug resistance surveillance using pooled pyrosequencing.
Mutation
298 20436677 The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.
Mutation
299 20453629 Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.
Mutation
300 20516563 Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Mutation
301 20532178 Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
Mutation
302 21487249 Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
Mutation
303 21516199 Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.
Mutation
304 21569325 The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.
Mutation
305 21663632 High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.
Mutation
306 21694608 Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
Mutation
307 21927716 Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.
Mutation
308 22110581 Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.
Mutation
309 22132100 Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Mutation
310 22293461 Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Mutation
311 22333046 The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.
Mutation
312 22448246 Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010.
Mutation
313 22877156 Clinical, epidemiological and molecular features of the HIV-1 subtype C and recombinant forms that are circulating in the city of São Paulo, Brazil.
Mutation
314 24465210 Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.
Mutation
315 24465566 Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications.
Mutation
316 24586665 Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.
Mutation
317 25003939 HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania.
Mutation
318 25170621 Functional analyses reveal extensive RRE plasticity in primary HIV-1 sequences selected under selective pressure.
Mutation
319 25259833 A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
Mutation
320 25303690 Evaluation of dried blood spots collected on filter papers from three manufacturers stored at ambient temperature for application in HIV-1 drug resistance monitoring.
Mutation
321 25397495 Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey.
Mutation
322 26020400 Genetic Characteristics of CRF01_AE Among Newly Diagnosed HIV-1-Infected 16- to 25-Year Olds in 3 Geographic Regions of Guangxi, China.
Mutation
323 27076106 HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults.
Mutation
324 27119150 HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Mutation
325 27177767 Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
Mutation
326 27231099 Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
Mutation
327 27338425 Viral Suppression and Resistance in a Cohort of Perinatally-HIV Infected (PHIV+) Pregnant Women.
Mutation
328 27704010 Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230.
Mutation
329 27997554 Drug Resistance and Virological Failure among HIV-Infected Patients after a Decade of Antiretroviral Treatment Expansion in Eight Provinces of China.
Mutation
330 28212411 Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
Mutation
331 28622345 The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014.
Mutation
332 28750025 HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China.
Mutation
333 28797181 HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania.
Mutation
334 29683855 A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Mutation
335 29739342 High prevalence of HIV-1 transmitted drug resistance among therapy-naïve Burmese entering travelers at Dehong ports in Yunnan, China.
Mutation
336 29977795 Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
Mutation
337 29977967 Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.
Mutation
338 30119633 Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Mutation
339 30201008 Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control.
Mutation
340 30223845 Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
Mutation
341 30315192 Antiretroviral resistance, genotypic characterization and origin of Human Immunodeficiency Virus among the infected wives of Intravenous drug users in Manipur.
Mutation
342 30325775 Sexual intermingling of Arab and Jewish MSM in Israel: results of a molecular epidemiology study.
Mutation
343 30364958 Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
Mutation
344 30409215 Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Mutation
345 30442114 Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Mutation
346 30461149 Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Mutation
347 30503324 Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
Mutation
348 30513108 Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
Mutation
349 30951600 Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Mutation
350 31262272 A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.
Mutation
351 31430369 Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Mutation
352 31479466 National survey of pre-treatment HIV drug resistance in Cuban patients.
Mutation
353 31516033 Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Mutation
354 31518723 Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience.
Mutation
355 31555932 Rapid Identification and Investigation of an HIV Risk Network Among People Who Inject Drugs -Miami, FL, 2018.
Mutation
356 31617907 Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Mutation
357 31774913 Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
Mutation
358 31914782 Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.
Mutation
359 31915714 Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment.
Mutation
360 31922125 Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).
Mutation
361 31988104 Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Mutation
362 32014042 Genetic characterization of HIV-1 epidemic in Anhui Province, China.
Mutation
363 32071061 Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.
Mutation
364 32119691 HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.
Mutation
365 32121161 Molecular Epidemiology of HIV-1 Infected Migrants Followed up in Portugal: Trends between 2001-2017.
Mutation
366 32138739 HIV drug resistance in patients in China's national HIV treatment programme who have been on first-line ART for at least 9 months.
Mutation
367 32156815 Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.
Mutation
368 32160290 Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.
Mutation
369 32183889 Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
Mutation
370 32205723 Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
Mutation
371 32321820 Impact of HLA-B*52:01-Driven Escape Mutations on Viral Replicative Capacity.
Mutation
372 32331438 HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia.
Mutation
373 32350342 Diverse HCV Strains And HIV URFS Identified Amongst People Who Inject Drugs In India.
Mutation
374 32381145 The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China.
Mutation
375 32408111 Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
Mutation
376 32457241 The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site.
Mutation
377 32555643 HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.
Mutation
378 32576136 Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study.
Mutation
379 32605062 Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping.
Mutation
380 32663847 Near Real-Time Identification of Recent Human Immunodeficiency Virus Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by Multiplexed Primer ID-Next-Generation Sequencing in North Carolina.
Mutation
381 32701823 Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Mutation
382 32761071 HIV drug resistance, phylogenetic analysis, and superinfection among men who have sex with men and transgender women in sub-Saharan Africa: HPTN 075.
Mutation
383 32843050 First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Mutation
384 32853364 Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Mutation
385 32873061 Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan.
Mutation
386 32874468 Detection of human immunodeficiency virus type 1 transmitted drug resistance among treatment-naive individuals residing in Jakarta, Indonesia.
Mutation
387 32894102 HIV-1 infection among women in Israel, 2010-2018.
Mutation
388 32929472 Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.
Mutation
389 32954411 Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
Mutation
390 32964671 Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors.
Mutation
391 32978684 In vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral-therapy-naïve HIV-infected men who have sex with men.
Mutation
392 32986709 Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania.
Mutation
393 32993693 Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia.
Mutation
394 33136751 Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Mutation
395 33166562 HIV-1 gp41 genetic diversity and enfuvirtide resistance-associated mutations among enfuvirtide-naïve patients in southern China.
Mutation
396 33287618 First Assessment of Acquired HIV-1 Drug Resistance and Mutation Patterns in Suriname.
Mutation
397 33297399 HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana.
Mutation
398 33315694 Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Mutation
399 33329467 Epidemiological and Molecular Characteristics of HIV-1 Infection in a Sample of Men Who Have Sex With Men in Brazil: Phylogeography of Major Subtype B and F1 Transmission Clusters.
Mutation
400 33952315 Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa.
Mutation
401 33943000 Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.
Mutation
402 33941212 Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Mutation
403 33892628 Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
Mutation
404 33880558 Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Mutation
405 33872329 Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis.
Mutation
406 33857166 High drug resistance levels could compromise the control of HIV infection in paediatric and adolescent population in Kinshasa, the Democratic Republic of Congo.
Mutation
407 33855355 Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
Mutation
408 33854982 Priority Intervention Targets Identified Using an In-Depth Sampling HIV Molecular Network in a Non-Subtype B Epidemics Area.
Mutation
409 33844760 [Prevalence of transmitted drug resistance in HIV-infected treatment-naive patients in Chile].
Mutation
410 33807382 HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.
Mutation
411 33805099 Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Mutation
412 33800773 Nef Obtained from Individuals with HIV-1 Vary in Their Ability to Antagonize SERINC3- and SERINC5-Mediated HIV-1 Restriction.
Mutation
413 33800269 Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals.
Mutation
414 33788308 HIV-1 subtypes and drug resistance in children during antiretroviral therapy in Brazil.
Mutation
415 33735301 Virological failure and antiretroviral resistance among HIV-infected children after five years follow-up in the ANRS 12225-PEDIACAM cohort in Cameroon.
Mutation
416 33734374 Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
Mutation
417 33724373 Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
Mutation
418 33722682 Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
Mutation
419 33693680 No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
Mutation
420 33692637 First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience.
Mutation
421 33686573 Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.
Mutation
422 33683148 Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.
Mutation
423 33679129 Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients in Southeast China.
Mutation
424 33668946 HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Mutation
425 33654530 Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
Mutation
426 33635848 Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.
Mutation
427 33635845 Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
Mutation
428 33632139 Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.
Mutation
429 33624081 Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).
Mutation
430 33603155 PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens.
Mutation
431 33592343 Transmitted drug resistance among HIV-1 drug-naïve patients in Greece.
Mutation
432 33561143 HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Mutation
433 33557775 HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China.
Mutation
434 33505382 Non-synonymous Substitutions in HIV-1 GAG Are Frequent in Epitopes Outside the Functionally Conserved Regions and Associated With Subtype Differences.
Mutation
435 33503987 Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013-2020.
Mutation
436 33480094 Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.
Mutation
437 33478415 Increase in HIV-1-transmitted drug resistance among ART-naïve youths at the China-Myanmar border during 2009 ~ 2017.
Mutation
438 33462791 HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil.
Mutation
439 33444376 The clarifying role of time series data in the population genetics of HIV.
Mutation
440 31879782 Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Mutation
441 31781759 Engagement in Care, Viral Suppression, Drug Resistance, and Reasons for Nonengagement After Home-Based Same-Day Antiretroviral Therapy Initiation in Lesotho: A Two-Year Follow-up of the CASCADE Trial.
Mutation
Contents
Description
Group Note
  • Mutation Tag: literature about this virus mutation and click the eye icon to see detail mutation information in literature
  • VIS-cistrome Tag: literature associated this virus integration and click the eye icon to see detail information of 3 cistrome factors (histone modification, transcription factor binding site and chromatin accessibility)